- Business Model
- B2B
- Website
- creyon.com
- Last Round
- Series AMar 2022
- Rounds
- 1
About
Creyon is developing a new class of cell-specific therapeutics using aptamer-delivered oligonucleotides engineered to deliver therapeutic payloads directly to T and B cells for immune-driven diseases. Its AI-Powered Nucleic Acid Engineering Platform (NucleIQ) combines proprietary pharmacology datasets with machine learning to design safe, targeted RNA therapies, including programs that cross the blood-brain barrier and a first-in-class treatment for late-onset Pompe disease.
Summary
Creyon is an Artificial Intelligence company based in United States. Its most recent funding was a Series A round in Mar 2022. Investors include DCVC (Data Collab), Lux Capital and Casdin Capital.
Tech & App Stack
4 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Mar 2022
Investors
Similar Companies
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
Asymchem is a pharmaceutical CDMO providing R&D, chemistry, manufacturing, and control services t...
OpenAI is an AI research and deployment company dedicated to ensuring that general-purpose artifi...
Anthropic develops reliable, interpretable, and steerable AI systems, translating frontier safety...
xAI builds AI systems, including Grok, with frontier reasoning, voice, and generative media capab...
Waymo is an autonomous driving technology company with a mission to make it safe and easy for peo...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/creyon"><img src="https://indexed.vc/api/badge/company/creyon" alt="Creyon on Indexed.vc" width="260" height="76" /></a>